Onkologische Schwerpunktpraxis Kurfuerstendamm
- Address
- lock Available on a paid plan
Breast Cancer Therapeutics
The site is conducting studies focused on advanced breast cancer, specifically targeting tumors that are ER(+)/HER2(-). These trials aim to compare new oral agents with established endocrine treatments to improve progression‑free survival and reduce recurrence risk.
- ARV-471 versus fulvestrant in advanced disease
- Imlunestrant versus standard adjuvant endocrine therapy in early‑stage patients
Onkologische Schwerpunktpraxis Kurfuerstendamm leverages its oncology expertise to evaluate innovative hormone‑targeted therapies for women with breast neoplasms.
Large B‑Cell Lymphoma Studies
Research at the Berlin clinic includes a range of DLBCL subtypes and related high‑grade B‑cell lymphomas. The primary goal is to assess whether adding novel agents to reduced‑intensity chemotherapy can extend progression‑free survival, especially in older or frail patients.
- Acalabrutinib combined with R‑miniCHOP in elderly DLBCL
- Exploration of targeted therapies across multiple B‑cell lymphoma variants
The department’s focus on hemic and lymphatic diseases supports the development of safer, more effective treatment options for patients with aggressive lymphomas.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 31 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1BeOne Medicines AG1active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1University Of Cologne2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Onkologische Schwerpunktpraxis Kurfuerstendamm
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults with Untreated Diffuse Large B-Cell Lymphoma (ARCHED/GLA 2022-1) | University Of Saarland | Phase III | Recruiting | Apr 2023 | — |
IMP list
lock Showing 1 of 31 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Acalabrutinib | 3 | Unknown | 2021-05-20 | 2024-06-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.